Multiple genome segments determine virulence of bluetongue virus serotype 8

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5238-5249

  Janowicz, Anna ^a   Caporale, Marco ^a,b   Shaw, Andrew ^a   Gulletta, Salvatore ^a   Di Gialleonardo, Luigina ^b   Ratinier, Maxime ^a   Palmarini, Massimo ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL ABRUZZO E DEL MOLISE G CAPORALE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN RECEPTOR; INTERFERON; NONSTRUCTURAL PROTEIN 3; PROTEIN VP2; RECEPTOR; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; IFNAR2 PROTEIN, MOUSE; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BLUETONGUE ORBIVIRUS; BLUETONGUE ORBIVIRUS SEROTYPE 8; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC CODE; GENETIC REASSORTMENT; GENETIC VARIABILITY; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS GENOME; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; BLUETONGUE; CELL LINE; CLASSIFICATION; DEFICIENCY; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; MOUSE; PATHOGENICITY; SEROTYPE; SHEEP; VIROLOGY; VIRULENCE; VIRUS CULTURE;

BLUETONGUE VIRUS; BLUETONGUE VIRUS 8; MUS; OVIS; OVIS ARIES;

ANIMALS; BLUETONGUE; BLUETONGUE VIRUS; CELL LINE; FEMALE; GENOME, VIRAL; INTERFERONS; MALE; MICE; MICE, KNOCKOUT; REASSORTANT VIRUSES; RECEPTOR, INTERFERON ALPHA-BETA; SEROGROUP; SHEEP; VIRAL PROTEINS; VIRULENCE; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84928566920     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00395-15     Document Type: Article

References (82)

1. Price DA, Hardy WT. 1954. Isolation of the bluetongue virus from Texas sheep-Culicoides shown to be a vector. J AmVet Med Assoc 124:255-258.
2. MacLachlan NJ, Drew CP, Darpel KE, Worwa G. 2009. The pathology and pathogenesis of bluetongue. J Comp Pathol 141:1-16. http://dx.doi.org/10.1016/j.jcpa.2009.04.003.
3. Mellor PS, Baylis M, Mertens PP. 2009. Bluetongue. Academic Press, London, United Kingdom.
4. Roy P, Noad R. 2006. Bluetongue virus assembly and morphogenesis. Curr Top Microbiol Immunol 309:87-116. http://dx.doi.org/10.1007/3-540-30773-7_4.
5. Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, Nunes SF, Armezzani A, Bayoumy A, Rixon F, Shaw A, Palmarini M. 2011. Identification and characterization of a novel non-structural protein of bluetongue virus. PLoS Pathog 7:e1002477. http://dx.doi.org/10.1371/journal.ppat.1002477.
6. Gouet P, Diprose JM, Grimes JM, Malby R, Burroughs JN, Zientara S, Stuart DI, Mertens PP. 1999. The highly ordered double-stranded RNA genome of bluetongue virus revealed by crystallography. Cell 97:481-490. http://dx.doi.org/10.1016/S0092-8674(00)80758-8.
7. Patel A, Roy P. 2014. The molecular biology of bluetongue virus replication. Virus Res 182:5-20. http://dx.doi.org/10.1016/j.virusres.2013.12.017.
8. Grimes JM, Jakana J, Ghosh M, Basak AK, Roy P, Chiu W, Stuart DI, Prasad BV. 1997. An atomic model of the outer layer of the bluetongue virus core derived from X-ray crystallography and electron cryomicroscopy. Structure 5:885-893. http://dx.doi.org/10.1016/S0969-2126(97)00243-8.
9. Roy P. 2008. Bluetongue virus: dissection of the polymerase complex. J Gen Virol 89:1789-1804. http://dx.doi.org/10.1099/vir.0.2008/002089-0.
10. Zhang X, Boyce M, Bhattacharya B, Schein S, Roy P, Zhou ZH. 2010. Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Proc Natl Acad Sci U S A 107:6292-6297. http://dx.doi.org/10.1073/pnas.0913403107.
11. Forzan M, Marsh M, Roy P. 2007. Bluetongue virus entry into cells. J Virol 81:4819-4827. http://dx.doi.org/10.1128/JVI.02284-06.
12. Hassan SH, Wirblich C, Forzan M, Roy P. 2001. Expression and functional characterization of bluetongue virus VP5 protein: role in cellular permeabilization. J Virol 75:8356-8367. http://dx.doi.org/10.1128/JVI.75.18.8356-8367.2001.
13. Owens RJ, Limn C, Roy P. 2004. Role of an arbovirus nonstructural protein in cellular pathogenesis and virus release. J Virol 78:6649-6656. http://dx.doi.org/10.1128/JVI.78.12.6649-6656.2004.
14. Monastyrskaya K, Gould EA, Roy P. 1995. Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein. J Virol 69:2831-2841.
15. Boyce M, Celma CC, Roy P. 2012. Bluetongue virus non-structural protein 1 is a positive regulator of viral protein synthesis. Virol J 9:178. http://dx.doi.org/10.1186/1743-422X-9-178.
16. Lymperopoulos K, Noad R, Tosi S, Nethisinghe S, Brierley I, Roy P. 2006. Specific binding of Bluetongue virus NS2 to different viral plusstrand RNAs. Virology 353:17-26. http://dx.doi.org/10.1016/j.virol.2006.04.022.
17. Kar AK, Bhattacharya B, Roy P. 2007. Bluetongue virus RNA binding protein NS2 is a modulator of viral replication and assembly. BMC Mol Biol 8:4. http://dx.doi.org/10.1186/1471-2199-8-4.
18. Butan C, Tucker P. 2010. Insights into the role of the non-structural protein 2 (NS2) in bluetongue virus morphogenesis. Virus Res 151:109-117. http://dx.doi.org/10.1016/j.virusres.2010.05.014.
19. Beaton AR, Rodriguez J, Reddy YK, Roy P. 2002. The membrane trafficking protein calpactin forms a complex with bluetongue virus protein NS3 and mediates virus release. Proc Natl Acad Sci U S A 99:13154-13159. http://dx.doi.org/10.1073/pnas.192432299.
20. Celma CC, Roy P. 2009. A viral nonstructural protein regulates bluetongue virus trafficking and release. J Virol 83:6806-6816. http://dx.doi.org/10.1128/JVI.00263-09.
21. Chauveau E, Doceul V, Lara E, Breard E, Sailleau C, Vidalain PO, Meurs EF, Dabo S, Schwartz-Cornil I, Zientara S, Vitour D. 2013. NS3 of bluetongue virus interferes with the induction of type I interferon. J Virol 87:8241-8246. http://dx.doi.org/10.1128/JVI.00678-13.
22. Huismans H, Erasmus BJ. 1981. Identification of the serotype-specific and group-specific antigens of bluetongue virus. Onderstepoort J Vet Res 48:51-58.
23. Kahlon J, Sugiyama K, Roy P. 1983. Molecular basis of bluetongue virus neutralization. J Virol 48:627-632.
24. Maan S, Maan NS, Nomikou K, Veronesi E, Bachanek-Bankowska K, Belaganahalli MN, Attoui H, Mertens PP. 2011. Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait. PLoS One 6:e26147. http://dx.doi.org/10.1371/journal.pone.0026147.
25. Shaw AE, Ratinier M, Nunes SF, Nomikou K, Caporale M, Golder M, Allan K, Hamers C, Hudelet P, Zientara S, Breard E, Mertens P, Palmarini M. 2013. Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment. J Virol 87:543-557. http://dx.doi.org/10.1128/JVI.02266-12.
26. Brenner J, Batten C, Yadin H, Bumbarov V, Friedgut O, Rotenberg D, Golender N, Oura CA. 2011. Clinical syndromes associated with the circulation of multiple serotypes of bluetongue virus in dairy cattle in Israel. Vet Rec 169:389. http://dx.doi.org/10.1136/vr.d4629.
27. Spreull J. 1905. Malarial catarrhal fever (bluetongue) of sheep in South Africa. J Comp Pathol Ther 18:321-339. http://dx.doi.org/10.1016/S0368-1742(05)80073-6.
28. Anderson GA, Stott JL, Gershwin LJ, Osburn BI. 1985. Subclinical and clinical bluetongue disease in cattle: clinical, pathological and pathogenic considerations. Prog Clin Biol Res 178:103-107.
29. Waldvogel AS, Anderson CA, Higgins RJ, Osburn BI. 1987. Neurovirulence of the UC-2 and UC-8 strains of bluetongue virus serotype 11 in newborn mice. Vet Pathol 24:404-410.
30. Parsonson IM. 1990. Pathology and pathogenesis of bluetongue infections. Curr Top Microbiol Immunol 162:119-141.
31. MacLachlan NJ. 1994. The pathogenesis and immunology of bluetongue virus-infection of ruminants. Comp Immunol Microbiol Infect Dis 17: 197-206. http://dx.doi.org/10.1016/0147-9571(94)90043-4.
32. Oura CA, Wood JL, Sanders AJ, Bin-Tarif A, Henstock M, Edwards L, Floyd T, Simmons H, Batten CA. 2009. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep. Vaccine 27:7326-7330. http://dx.doi.org/10.1016/j.vaccine.2009.09.070.
33. Caporale M, Di Gialleonorado L, Janowicz A, Wilkie G, Shaw A, Savini G, Van Rijn PA, Mertens P, Di Ventura M, Palmarini M. 2014. Virus and host factors affecting the clinical outcome of bluetongue virus infection. J Virol 88:10399-10411. http://dx.doi.org/10.1128/JVI.01641-14.
34. Elbers A, Backx A, van der Spek A, Ekker M, Leijs P, Steijn K, van Langen H, van Rijn P. 2008. Epidemiology of bluetongue virus serotype 8 outbreaks in the Netherlands in 2006. Tijdschr Diergeneeskd 133:222-229. (In Dutch.).
35. Elbers AR, Backx A, Mintiens K, Gerbier G, Staubach C, Hendrickx G, van der Spek A. 2008. Field observations during the bluetongue serotype 8 epidemic in 2006. II. Morbidity and mortality rate, case fatality and clinical recovery in sheep and cattle in the Netherlands. Prev Vet Med 87:31-40. http://dx.doi.org/10.1016/j.prevetmed.2008.06.003.
36. Perrin JB, Ducrot C, Vinard JL, Morignat E, Gauffier A, Calavas D, Hendrikx P. 2010. Using the National Cattle Register to estimate the excess mortality during an epidemic: application to an outbreak of bluetongue serotype 8. Epidemics 2:207-214. http://dx.doi.org/10.1016/j.epidem.2010.10.002.
37. Coetzee P, Van Vuuren M, Stokstad M, Myrmel M, Venter EH. 2012. Bluetongue virus genetic and phenotypic diversity: towards identifying the molecular determinants that influence virulence and transmission potential. Vet Microbiol 161:1-12. http://dx.doi.org/10.1016/j.vetmic.2012.07.007.
38. Moulin V, Noordegraaf CV, Makoschey B, van der Sluijs M, Veronesi E, Darpel K, Mertens PP, de Smit H. 2012. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine. Vaccine 30:2228-2235. http://dx.doi.org/10.1016/j.vaccine.2011.11.100.
39. Caporale M, Wash R, Pini A, Savini G, Franchi P, Golder M, Patterson-Kane J, Mertens P, Di Gialleonardo L, Armillotta G, Lelli R, Kellam P, Palmarini M. 2011. Determinants of bluetongue virus virulence in murine models of disease. J Virol 85:11479-11489. http://dx.doi.org/10.1128/JVI.05226-11.
40. Arnaud F, Black SG, Murphy L, Griffiths DJ, Neil SJ, Spencer TE, Palmarini M. 2010. Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J Virol 84:4415-4425. http://dx.doi.org/10.1128/JVI.00029-10.
41. Varela M, Schnettler E, Caporale M, Murgia C, Barry G, McFarlane M, McGregor E, Piras IM, Shaw A, Lamm C, Janowicz A, Beer M, Glass M, Herder V, Hahn K, Baumgartner W, Kohl A, Palmarini M. 2013. Schmallenberg virus pathogenesis, tropism and interaction with the innate immune system of the host. PLoS Pathog 9:e1003133. http://dx.doi.org/10.1371/journal.ppat.1003133.
42. Boyce M, Celma CC, Roy P. 2008. Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J Virol 82:8339-8348. http://dx.doi.org/10.1128/JVI.00808-08.
43. Nunes SF, Hamers C, Ratinier M, Shaw A, Brunet S, Hudelet P, Palmarini M. 2014. A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus. J Virol 88:12222-12232. http://dx.doi.org/10.1128/JVI.02183-14.
44. Maan S, Rao S, Maan NS, Anthony SJ, Attoui H, Samuel AR, Mertens PP. 2007. Rapid cDNA synthesis and sequencing techniques for the genetic study of bluetongue and other dsRNA viruses. J Virol Methods 143: 132-139. http://dx.doi.org/10.1016/j.jviromet.2007.02.016.
45. Li H, Ruan J, Durbin R. 2008. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 18:1851-1858. http://dx.doi.org/10.1101/gr.078212.108.
46. Milne I, Bayer M, Cardle L, Shaw P, Stephen G, Wright F, Marshall D. 2010. Tablet-next generation sequence assembly visualization. Bioinformatics 26:401-402. http://dx.doi.org/10.1093/bioinformatics/btp666.
47. Baranowski E, Sevilla N, Verdaguer N, Ruiz-Jarabo CM, Beck E, Domingo E. 1998. Multiple virulence determinants of foot-and-mouth disease virus in cell culture. J Virol 72:6362-6372.
48. Mertens PP, Pedley S, Cowley J, Burroughs JN, Corteyn AH, Jeggo MH, Jennings DM, Gorman BM. 1989. Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype. Virology 170:561-565. http://dx.doi.org/10.1016/0042-6822(89)90447-9.
49. Maan S, Maan NS, van Rijn PA, van Gennip RG, Sanders A, Wright IM, Batten C, Hoffmann B, Eschbaumer M, Oura CA, Potgieter AC, Nomikou K, Mertens PP. 2010. Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains. PLoS One 5:e10323. http://dx.doi.org/10.1371/journal.pone.0010323.
50. Wilson AJ, Mellor PS. 2009. Bluetongue in Europe: past, present and future. Philos Trans R Soc Lond B Biol Sci 364:2669-2681. http://dx.doi.org/10.1098/rstb.2009.0091.
51. Celma CC, Bhattacharya B, Eschbaumer M, Wernike K, Beer M, Roy P. 2014. Pathogenicity study in sheep using reverse-genetics-based reassortant bluetongue viruses. Vet Microbiol 174:139-147. http://dx.doi.org/10.1016/j.vetmic.2014.09.012.
52. Nason EL, Rothagel R, Mukherjee SK, Kar AK, Forzan M, Prasad BV, Roy P. 2004. Interactions between the inner and outer capsids of bluetongue virus. J Virol 78:8059-8067. http://dx.doi.org/10.1128/JVI.78.15.8059-8067.2004.
53. Bhattacharya B, Roy P. 2008. Bluetongue virus outer capsid protein VP5 interacts with membrane lipid rafts via a SNARE domain. J Virol 82: 10600-10612. http://dx.doi.org/10.1128/JVI.01274-08.
54. Gould AR, Eaton BT. 1990. The amino acid sequence of the outer coat protein VP2 of neutralizing monoclonal antibody-resistant, virulent and attenuated bluetongue viruses. Virus Res 17:161-172. http://dx.doi.org/10.1016/0168-1702(90)90062-G.
55. Gould AR, Hyatt AD, Eaton BT. 1988. Morphogenesis of a bluetongue virus variant with an amino acid alteration at a neutralization site in the outer coat protein, VP2. Virology 165:23-32. http://dx.doi.org/10.1016/0042-6822(88)90654-X.
56. Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 72:7357-7366.
57. Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. 2014. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719. http://dx.doi.org/10.1371/journal.pntd.0002719.
58. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75:5627-5637. http://dx.doi.org/10.1128/JVI.75.12.5627-5637.2001.
59. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. http://dx.doi.org/10.1006/viro.2000.0546.
60. Byrnes AP, Griffin DE. 2000. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J Virol 74:644-651. http://dx.doi.org/10.1128/JVI.74.2.644-651.2000.
61. Lee E, Wright PJ, Davidson A, Lobigs M. 2006. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87:2791-2801. http://dx.doi.org/10.1099/vir.0.82164-0.
62. Olmsted RA, Baric RS, Sawyer BA, Johnston RE. 1984. Sindbis virus mutants selected for rapid growth in cell culture display attenuated virulence in animals. Science 225:424-427. http://dx.doi.org/10.1126/science.6204381.
63. Huismans H. 1969. Bluetongue virus-induced interferon synthesis. Onderstepoort J Vet Res 36:181-185.
64. Jameson P, Schoenherr CK, Grossberg SE. 1978. Bluetongue virus, an exceptionally potent interferon inducer in mice. Infect Immun 20:321-323.
65. MacLachlan NJ, Thompson J. 1985. Bluetongue virus-induced interferon in cattle. Am J Vet Res 46:1238-1241.
66. Ruscanu S, Pascale F, Bourge M, Hemati B, Elhmouzi-Younes J, Urien C, Bonneau M, Takamatsu H, Hope J, Mertens P, Meyer G, Stewart M, Roy P, Meurs EF, Dabo S, Zientara S, Breard E, Sailleau C, Chauveau E, Vitour D, Charley B, Schwartz-Cornil I. 2012. The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway. J Virol 86:5817-5828. http://dx.doi.org/10.1128/JVI.06716-11.
67. Ortego J, de la Poza F, Marin-Lopez A. 2014. Interferon alpha/beta receptor knockout mice as a model to study bluetongue virus infection. Virus Res 182:35-42. http://dx.doi.org/10.1016/j.virusres.2013.09.038.
68. Calvo-Pinilla E, Nieto JM, Ortego J. 2010. Experimental oral infection of bluetongue virus serotype 8 in type I interferon receptor-deficient mice. J Gen Virol 91:2821-2825. http://dx.doi.org/10.1099/vir.0.024117-0.
69. Sutton G, Grimes JM, Stuart DI, Roy P. 2007. Bluetongue virus VP4 is an RNA-capping assembly line. Nat Struct Mol Biol 14:449-451. http://dx.doi.org/10.1038/nsmb1225.
70. Ramadevi N, Burroughs NJ, Mertens PP, Jones IM, Roy P. 1998. Capping and methylation of mRNA by purified recombinant VP4 protein of bluetongue virus. Proc Natl Acad Sci U S A 95:13537-13542. http://dx.doi.org/10.1073/pnas.95.23.13537.
71. Garcia-Sastre A. 2011. 2 Methylate or not 2 methylate: viral evasion of the type I interferon response. Nat Immunol 12:114-115. http://dx.doi.org/10.1038/ni0211-114.
72. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zust R, Dong H, Thiel V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller RM, Gale M, Jr, Shi PY, Diamond MS. 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468:452-456. http://dx.doi.org/10.1038/nature09489.
73. Zust R, Dong H, Li XF, Chang DC, Zhang B, Balakrishnan T, Toh YX, Jiang T, Li SH, Deng YQ, Ellis BR, Ellis EM, Poidinger M, Zolezzi F, Qin CF, Shi PY, Fink K. 2013. Rational design of a live attenuated dengue vaccine: 2'-O-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog 9:e1003521. http://dx.doi.org/10.1371/journal.ppat.1003521.
74. Perez-Cidoncha M, Killip MJ, Oliveros JC, Asensio VJ, Fernandez Y, Bengoechea JA, Randall RE, Ortin J. 2014. An unbiased genetic screen reveals the polygenic nature of the influenza virus anti-interferon response. J Virol 88:4632-4646. http://dx.doi.org/10.1128/JVI.00014-14.
75. Hoshino Y, Saif LJ, Kang SY, Sereno MM, Chen WK, Kapikian AZ. 1995. Identification of group A rotavirus genes associated with virulence of a porcine rotavirus and host range restriction of a human rotavirus in the gnotobiotic piglet model. Virology 209:274-280. http://dx.doi.org/10.1006/viro.1995.1255.
76. Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Aranda CA, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, Feldmann H. 2011. Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J Virol 85:1214-1223. http://dx.doi.org/10.1128/JVI.01848-10.
77. Clements ML, Subbarao EK, Fries LF, Karron RA, London WT, Murphy BR. 1992. Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol 30:655-662.
78. Griot C, Gonzalez-Scarano F, Nathanson N. 1993. Molecular determinants of the virulence and infectivity of California serogroup bunyaviruses. Annu Rev Microbiol 47:117-138. http://dx.doi.org/10.1146/annurev.mi.47.100193.001001.
79. Janssen RS, Nathanson N, Endres MJ, Gonzalez-Scarano F. 1986. Virulence of La Crosse virus is under polygenic control. J Virol 59:1-7.
80. Rott R. 1980. Genetic determinants for infectivity and pathogenicity of influenza viruses. Philos Trans R Soc Lond B Biol Sci 288:393-399. http://dx.doi.org/10.1098/rstb.1980.0016.
81. Scholtissek C, Vallbracht A, Flehmig B, Rott R. 1979. Correlation of pathogenicity and gene constellation of influenza A viruses. II. Highly neurovirulent recombinants derived from non-neurovirulent or weakly neurovirulent parent virus strains. Virology 95:492-500.
82. Snyder MH, Betts RF, DeBorde D, Tierney EL, Clements ML, Herrington D, Sears SD, Dolin R, Maassab HF, Murphy BR. 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62:488-495.